45 results about "Enteric coated" patented technology

The invention relates to a pharmaceutical composition comprising benzgalantamine and uses and methods for the preparation thereof. The present invention provides a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. The pharmaceutical composition could be used in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further provides a method for preparing the pharmaceutical composition.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

The invention belongs to the technical field of materials, discloses a preparation method and application of novel stomach and intestinal tract passing sustained-release tannic acid, and particularly discloses a stomach and intestinal tract passing enteric coating material which comprises a surfactant, sugar alcohol, hydrogenated grease, polyacrylic resin and a thickening agent. The stomach-passing enteric coating material does not use expensive commercially available enteric coating materials, but adopts common surfactants, sugar alcohol substances and other substances, so that the grease and the water can be better fused, and the grease can be better coated outside in the coating process. The stomach-passing enteric coating material can ensure that tannic acid is not damaged by gastric acid, reduces the influence on animal digestive enzymes, and can be slowly released in intestinal tracts to be absorbed and utilized.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

The disclosed composition consists of 15 mg Ferula asafetida (Hing) oil as an active ingredient, 85 mg Frankincense oil and 400 mg coconut oil as in-active ingredients in an enteric coated HPMC capsule form. The process of preparation consists of steps of blending asafetida (hing) oil with Frankincense oil and coconut oil followed by dispensing the blended oils into empty HPMC capsule shell, which are automatically filled in liquid filling machine. Further a banding solution containing 0.025 ml HPMC (surfactant), 2.8 mg IPA (Binding Agent) and 0.03 mg Chocolate brown color (colorant) are filled into the bath of band sealing machine at room temperature where the hing oil containing capsules are band sealed. The disclosed oral formulation in the form of HPMC capsule is natural, low cost, highly efficacious and quick in management primary dysmenorrhea.

The invention relates to the technical field of pet feed additives, and discloses a pet coated enzyme-containing metagen feed additive and a preparation method thereof, the additive comprises a core particle formed by mixing a metagen and a slow-release coated compound enzyme, and an enteric layer coated outside the core particle. The preparation method comprises the following steps: respectively preparing the metagen and the slow-release coated compound enzyme, mixing the metagen and the slow-release coated compound enzyme to prepare core particles, and then carrying out enteric coating on the core particles. The activity of functional components is protected through a double coating structure, so that the functional components are released in an intestinal tract in a targeted manner and have a synergistic effect. The additive can effectively improve pet protein digestion, regulate intestinal microenvironment, remarkably proliferate beneficial bacteria such as lactobacillus and clostridium praeparatum and inhibit escherichia coli, so that soft stool is reduced, and intestinal health of pets is maintained.

The invention discloses a mesoporous polydopamine (MPDA) nanoparticle which is loaded with a CeO2 nano enzyme and mitoxantrone mesylate (MitoQ) and is released by an intestinal tract, a preparation method of the mesoporous polydopamine (MPDA) nanoparticle, and an application of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle and the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, and the preparation method of the mesoporous polydopamine (MPDA) nanoparticle. The mesoporous polydopamine nanoparticle loaded with the CeO2 nano enzyme and the mitoxantrone mesylate and released by the intestinal tract comprises mesoporous polydopamine loaded with the CeO2 nano enzyme and MitoQ, and an enteric coating of chitosan and sodium alginate. The preparation method comprises the following steps: synthesizing mesoporous polydopamine by adopting a triblock copolymer as a template, then loading a small molecular drug MitoQ into MPDA through ultrasonic waves, and loading CeO2 nano-enzyme on the surface of MPDA through metal coordination to form MPDA (at) CeO2-MitoQ. And finally, coating chitosan and sodium alginate on the surfaces of the nanoparticles through electrostatic adsorption to obtain the final MPDA (at) CeO2-MitoQ (at) SA / CS. The drug-loaded nano-particles prepared by the preparation method disclosed by the invention have a good treatment effect on ulcerative colitis.

Composition of vitamin C and elderberry extract in a prolonged-release system for enhanced immune support, comprising: a) 400 mg vitamin C (ascorbic acid), b) 150 mg elderberry extract standardized to anthocyanins, c) 15 mg zinc gluconate, d) 100 mg echinacea extract standardized to polysaccharides, e) 100 mg quercetin, f) 300 mg hydroxypropyl methylcellulose, g) 50 mg microcrystalline cellulose, h) 30 mg cross-linked polyvinylpyrrolidone, i) 5 mg magnesium stearate, j) 5 mg of a black pepper extract standardized to piperine, and k) 20 mg of an enteric coating agent.

A metformin hydrochloride enteric-coated tablet, which consists of a tablet core containing a therapeutically effective amount of metformin hydrochloride and an enteric coating layer wrapping the tablet core, and has a metformin hydrochloride dissolution of not higher than 15% within 2 hours in a pH 4.5 medium and a metformin hydrochloride dissolution of not less than 85% within 20 minutes in a pH 6.8 medium. The metformin hydrochloride enteric-coated tablet, which meets specific drug release technical requirements, is obtained by means of selecting the disintegration time limit of the tablet core, the dissolution point of the enteric coating material and the weight gain of the coating. Compared with common preparations of metformin hydrochloride (such as glucophage) and enteric-coated tablets having other release characteristics, the metformin hydrochloride enteric-coated tablet improves the tolerance and compliance of metformin hydrochloride without reducing the hypoglycemic efficacy.

The invention discloses an enteric coated enterobacteria microcapsule and a preparation method thereof, the enteric coated enterobacteria microcapsule is composed of a capsule core, an isolating layer coating and an enteric layer coating from inside to outside in sequence, the capsule core contains enterobacteria sludge; the isolating layer is prepared from non-ionic cellulose mixed ether, talcum powder, nano titanium dioxide, glycerol triacetate and water, and an isolating layer coating solution is prepared and wraps the outer surface of the capsule core; the enteric-coated layer is an enteric-coated layer coating solution which is prepared from knot / rectum-soluble Eudragit, talcum powder, TEC and an alcohol solvent, and the enteric-coated layer coating solution is coated on the outer surface of the isolating layer. The enteric coated enterobacteria microcapsule can effectively improve the bioavailability and stability of enterobacteria, and provides an efficient oral dosage form for intestinal flora transplantation.

To provide an oral formulation of parathyroid hormone analog.SOLUTION: The present invention relates to method of preventing or treating disease or disorder comprising administration of oral pharmaceutical composition comprising therapeutically effective amount of parathyroid hormone (PTH) analog and at least one degradation preventing agent, wherein said composition provides relative bioavailability of at least 0.5%, compare to subcutaneous administration. The present invention also relates to the oral pharmaceutical composition comprising therapeutically effective amount of PTH analog and least one degradation preventing agent in physically separated dosage form and wherein said PTH analogue is in enteric coated form. At least one degradation preventing agent includes combination of at least one metal containing compound and at least one reducing agent where in at least one metal containing compound is selected for group consisting of vanadium containing compound, chromium containing compound and manganese containing compound. Preferably PTH analogue are teriparatide or abaloparatide.SELECTED DRAWING: Figure 1

The disclosed technology includes a surgical adjunct 604 that includes a polyurethane foam comprising a volumetric ratio of the polyurethane foam to the total volume of the surgical adjunct 604 is in a range of about 0.125 to about 0.325, and at least one hydrophobicity additive comprising at least one ceramic nanoparticle, at least one fatty acid, at least one ionic liquid, at least one long chain surfactant, at least one enteric coating, at least one photocurable resin, or combinations thereof.

The utility model discloses an efficient dusting machine for enteric-coated tablet production, which relates to the technical field of medicine production and comprises a vehicle body, universal wheels are fixedly mounted below the vehicle body, a handle is fixedly mounted on the side surface of the vehicle body, a baffle is fixedly mounted in the vehicle body, and a negative pressure suction head is detachably mounted at the top of the vehicle body. A guide pipe is fixedly installed at the bottom of the negative pressure suction head, a through hole is formed in the top of the vehicle body, the guide pipe penetrates through the vehicle body, a dust suction pipe is fixedly installed on the left side of the baffle, a pipe hoop is arranged between the dust suction pipe and the guide pipe and is in threaded connection with the dust suction pipe and the guide pipe, the dust suction pipe penetrates through the baffle, and the right side of the baffle is filled with alkali liquor. According to the powder cleaning vehicle, powder in a workshop can be cleaned, the influence of excessive powder in the workshop on the body health of production personnel is avoided, the powder cleaning vehicle is easy and convenient to disassemble and convenient to clean, and the dust removal efficiency is improved.

The invention discloses an oral vaccine as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The oral vaccine comprises a core, and a permeation enhancing layer, an active molecular layer and an enteric coating layer which are sequentially coated on the surface of the core, the core is a biodegradable polymer nano particle; the permeation enhancing layer is a polydopamine layer loaded with a permeation enhancer; the active molecular layer is a chitosan layer loaded with an antigen and a targeting substance. The oral vaccine provided by the embodiment of the invention is good in stability, can ensure that the antigen is stable in gastrointestinal tracts and keeps activity, realizes targeted release of intestinal tracts, can activate far-end mucous membrane tissues at the same time, realizes broad-spectrum IgA and IgG immunization, and is suitable for delivery of various oral antigens.

A soft gel capsule includes a filler material, a shell composition, and a coating having an enteric polymer wherein the coating provides a weight gain of the capsule from about 1% to about 10%. The coating improves the robustness of the enteric solubility of the soft gel capsule and maximally reduces the hygroscopicity of the soft gel capsule in the dissolving process.

The present invention relates to the technical field of biotin preparations, and specifically discloses a biotin dispersion and a composition thereof, wherein the raw materials of the biotin dispersion include by weight: 1-10 parts of biotin, 80-120 parts of hydrophilic polymers, and 0.01-1 parts of disodium hydrogen phosphate. The present invention also discloses that the raw materials of the above-mentioned biotin dispersion composition include by weight: 80-135 parts of the biotin dispersion, 200-300 parts of lactose, 5-15 parts of povidone K30, 100-120 parts of enteric coating polymers, 1-5 parts of propylene glycol, and 80-100 parts of talc. The preparation process of the present invention is simple, not only the stability during the preparation process is good, but also biotin can be directly absorbed and utilized by the small intestine, which improves its absorption rate and bioavailability, and is suitable for large-scale production.

To provide a solid preparation that contains lactoferrin and cells of Lacticaseibacillus casei but does not show a decrease in in-vivo collapsibility.SOLUTION: A solid preparation comprising (A) lactoferrin, (B) cells of Lacticaseibacillus casei, and (C) an excipient, where the excipient (C) comprises (C1) at least one of cellulose or a derivative thereof and (C2) at least one sugar alcohol.SELECTED DRAWING: None

The utility model relates to the technical field of health food production, and discloses a tablet health food enteric coating device which comprises a base, a driving motor is fixedly installed on the upper surface of the base, a gear is sleeved on the outer surface of an output shaft of the driving motor, the outer surface of the gear is connected with a gear ring in a meshed mode, and a coating tank is sleeved on the inner surface of the gear ring. The outer surface of the coating tank is sleeved with a circular sliding rail, the outer surface of the circular sliding rail is slidably connected with an auxiliary pulley, the auxiliary pulley is fixedly installed on the upper surface of the base, a storage box is fixedly installed on the upper surface of the base, the coating tank is rotationally connected to the upper surface of the base, and a feeding table is fixedly installed on the upper surface of the base. According to the tablet health-care food enteric coating device, tablets are prevented from being accumulated during coating by driving the guide plate to vibrate, the problem that the coated tablets are difficult to feed can be effectively solved, the coated tablets cannot be accumulated to block the feed port during feeding, feeding can be smoother, and the tablet health-care food enteric coating device is more convenient and practical.

The present invention relates to a sustained-release enteric coating pellet and a method for manufacturing same and, more specifically, to a sustained-release enteric coating pellet and a method for manufacturing same, the sustained-release enteric coating pallet comprising: an inert core; a coating layer of an active ingredient formed on the core; a sustained-release coating layer formed on the coating layer of the active ingredient; and an enteric coating layer formed on the sustained-release coating layer, wherein: the active ingredient is tamsulosin or a pharmaceutically acceptable salt thereof; the sustained-release coating layer comprises a sustained-release agent and a coating stabilizer; the coating stabilizer is polyvinyl alcohol, such that the pellet allows for the sustained release in a continuous and stable manner under enteric conditions and exhibits high reproducibility even when manufactured under various environmental or process conditions.

The application discloses a bactericidal and anti-inflammatory multi-layer microneedle patch with programmed response and a preparation method, and relates to the technical field of biomedical materials and wound repair. The microneedle patch comprises an outer shell layer, a core layer and a sandwich layer, the sandwich layer wraps the core layer, and the outer shell layer is coated outside the needle body of the sandwich layer. The component of the core layer is PVP and PVA loaded curcumin nanoparticles. The component of the outer shell layer is PVP and PVA loaded copper chloride. The sandwich layer is an enteric coating. The preparation method adopts reverse combination from solid to liquid, the solidified inner core is used as a male die, and is directly added to an un-solidified solution in a female die to form a mechanical interlocking structure. The application realizes layered time-sequencing drug delivery under multi-signal response, has good antibacterial, anti-inflammatory and wound healing abilities, and good mechanical properties, biocompatibility and large-scale preparation potential, and can significantly improve the antibacterial and repair efficiency of chronic wounds.

The invention provides an enteric-coated tablet for treating neuritis and a preparation method of the enteric-coated tablet. The enteric-coated tablet is prepared from the following components in percentage by weight: 0.01%-1% of mecobalamin, 60%-80% of butanedisulfonic acid adenosyl methionine, 10%-30% of a diluent, 4%-9% of an adhesive, 1%-5% of a disintegrating agent, 0.1%-1% of a lubricant and 8%-16% of an enteric-coated material. The enteric-coated tablet disclosed by the invention is simple in production process, universal in production equipment and low in cost, mainly overcomes the defect of large in-vivo absorption difference, and has a remarkable curative effect on treating neuritis.

The invention relates to the technical field of medical drugs, and particularly discloses a choline fenofibrate sustained-release capsule and a preparation method thereof. The choline fenofibrate sustained-release capsule comprises a drug-containing pill core, a sustained-release coating film, an enteric coating film and a hollow capsule, the medicine-containing pellet core comprises a pellet core, fenofibric acid choline, a film-forming solution and an adhesive; a film-forming material in the film-forming solution is prepared by sequentially modifying hydroxy propyl cellulose with sodium alginate and a silane coupling agent. The hydroxy propyl cellulose contains hydroxyl and can be cross-linked and grafted with carboxyl on the sodium alginate, so that the compactness of the drug-containing coating layer is improved; the silane coupling agent is hydrolyzed to generate silanol groups, the silanol groups and hydroxyl groups in the hydroxy propyl cellulose or the sodium alginate can form hydrogen bonds, the hydrogen bonds are adsorbed on the hydroxy propyl cellulose or the sodium alginate, and in the drying process of subsequent preparation, the hydrogen bonds and the silanol groups are subjected to dehydration condensation to form a three-dimensional network structure; the adhesion and compactness of the subsequent sustained-release coating film and the enteric coating film are improved, so that the medicine is further slowly released.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

The present disclosure provides a gastric resistant, enteric coated nano-silica yeast particle (YP) delivery system. The disclosure further provides methods of making and methods of using a nano-silica yeast particle delivery system.

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral / alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

The invention belongs to the field of anti-aging, and particularly relates to an anti-aging capsule containing ergothioneine and a preparation method of the anti-aging capsule. According to the invention, beta-cyclodextrin is used for inclusion of ergothioneine to block an oxidation path; meanwhile, resveratrol-chitosan is used as a slow-release regulation and control layer, burst release is inhibited, and the dual functions of oxidation resistance and light / oxygen blocking on ergothioneine are achieved; finally, an EudragS100 enteric coating is adopted as a gastric acid protection layer, a compact structure is formed when the pH value is smaller than 7, gastric juice permeation is reduced, and therefore a three-level protection system from molecular inclusion to physical isolation and then to targeted slow release is formed.

The present application relates to the technical field of pet feed additives, and discloses a pet coated postbiotic feed additive containing enzymes and a preparation method, the additive comprising core particles formed by mixing postbiotics and complex enzymes coated with a slow-release coating, and an enteric layer coated on the outside of the core particles. The preparation method comprises: preparing the postbiotics and the slow-release coated complex enzymes respectively, mixing the two to form core particles, and then enteric coating the core particles. The present application protects the activity of functional components through a double-coating structure, so that the functional components are released in the intestinal tract and synergize. The additive can effectively improve the digestion of pet protein, regulate the intestinal microenvironment, significantly proliferate beneficial bacteria such as lactobacillus and prasrmanella, and inhibit escherichia coli, thereby reducing soft stool and maintaining the intestinal health of pets.

An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.

Embodiments herein provide a pharmaceutical formulation comprising an anti-inflammatory antipyretic agent with reduced side effects, addressing gastric problems. An enteric-coated tablet of the present invention comprises esomeprazole, aceclofenac, and paracetamol, along with maize starch, microcrystalline cellulose, povidone K30, colloidal anhydrous silica, and magnesium stearate.